Summary The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with SCLC relapsing within 3 months of cytotoxic therapy received paclitaxel 175 mg m-2 intravenously over 3 h every 3 weeks. The dose of paclitaxel was adjusted to the toxicity encountered in the previous cycle. Of 24 patients entered into the study, 24 and 21 were assessable for response and toxicity respectively. There were two early deaths and two toxic deaths. No complete and seven partial responses (29%) (95%CI 12-51%) were observed and five patients had disease stabilization. The median survival (n = 21) was 100 days. Life-threatening toxicity occurred in four patients; in others (non)-haematological toxicity was manageable. Paclitaxel is active in drug-resistant SCLC. Further investigation in combination with other active agents in this poor prognosis group is appropriate.
With present-day chemo-and radiotherapy regimens, a major response with considerable prolongation of survival (Ihde, 1992) will be achieved in 90-95% of patients with small-cell lung cancer (SCLC) . However, in the majority of these patients the tumour will relapse after a shorter or longer treatment-free period. In this situation, second-line treatment is necessary for adequate palliation. A multifocal relapse will usually lead to treatment with chemotherapy (Andersen et al, 1990) . It is then necessary to distinguish between patients with tumours that are sensitive and patients with tumours presumably resistant to cytotoxic agents used in the induction phase (Giaccone, 1989) . Patients relapsing within 3 months of induction chemotherapy are considered resistant to the drugs used in the induction regimen (Postmus et al, 1987; Smit et al, 1989 ). For such patients, second-line treatment should consist off non-cross-resistant drugs. The poor results currently obtained by second-line chemotherapy support the view that failure to identify real non-cross-resistant agents is the primary reason for lack of success (Andersen et al, 1990) . Further evidence for this view comes from the fact that, although in most studies on second-line chemotherapy it is not specifically stated, most therapy-resistant patients responding to a second-line regimen have shown a previous response of short duration to first-line treatment (Smit et al, 1989; Postmus, 1993) . Thus, there is a great need for new active agents in the setting of second-line treatment in so-called therapy-resistant patients. Moreover, identification of such agents may lead to the development of more potent first-line regimens.
Paclitaxel (taxol) is a new drug with established activity in resistant solid tumours, such as platinum-resistant ovarian cancer and anthracylin-resistant breast cancer (Rowinsky et al, 1995) . In addition, it has shown considerable anti-tumour activity in chemotherapy naive patients with SCLC (Kirschling et al, 1994; Ettinger et al, 1995) . Therefore, we initiated a phase II trial of paclitaxel (taxol) in patients with clinically resistant SCLC, which is the subject of this report.
PATIENTS AND METHODS
The trial was approved by the local Medical Ethics Committees. All patients gave informed consent before they were enrolled into the study.
Eligibility criteria
Patients were considered eligible when they met all of the following criteria: age between 18 and 75 years; histologically or cytologically proven SCLC; last cytotoxic treatment less than 3 months before entry; ECOG performance status 0-3; WBC > 3.0 x 109 1-1; platelet count > 100 x 109 1-1 (unless lower values were because of bone marrow involvement); creatinine clearance according to the Cockroft method > 60 ml min-'; bilirubin level less than 25 ,umol 1-1; and bidimensionally measurable disease. Exclusion criteria included significant cardiac disease, uncontrolled infection and concurrent cytotoxic chemotherapy. Concurrent radiotherapy was allowed for, provided that not all measurable lesions were included in the irradiated field. Paclitaxel 175 mg m-2 was administered as a 3-h i.v. infusion every 21 days. This paclitaxel dose was chosen in view of the chemotherapeutic and radiotherapeutic pretreatment and the short interval between the last treatment and inclusion into this study. The subsequent dose was modified according to toxicity in the previous course for each individual patient. A dose reduction to 150 mg m-2 was applied when the WBC count was < 1.0 x 109 1-or platelet counts < 25 x 109 1-' for more than 1 week or in the case of febrile neutropenia. A dose escalation to 200 mg m-2 was applied when WBC count was > 3.0 x 109 1-' and platelet count > 75 x 109 1-1 during the previous cycle. When WHO grade IV myelotoxicity occurs, at this dose level, a dose of 175 mg m-2 was to be administered in the subsequent cycle.
Pretreatment evaluation
Therapy was administered for a maximum of five cycles. Patients went off-study in cases of disease progression, incomplete haematological recovery 2 weeks after scheduled re-treatment, WHO grade III neuropathy or any other non-haematological toxicity WHO grade IV except alopecia.
Evaluation during treatment
Before each new administration of paclitaxel a physical examination, assessment of performance status, laboratory tests, ECG and chest radiograph or any other investigation necessary for assessment of response was obtained. A complete blood cell count on days 10 and 14 was obtained between two courses of paclitaxel.
Response assessment
A complete response was defined as the complete resolution of all signs of known disease for a minimum of 4 weeks. A partial response was defined as a more than 50% reduction in the sum of the products of the largest perpendicular diameters of all measurable lesions for a minimum of 4 weeks. The term stable disease was given to patients who failed to fulfil the criteria for partial response in the absence of disease progression. Disease progression was defined as an increase > 25% in the sum of the products of the largest perpendicular diameters of all measurable lesions or the occurrence of any new lesion.
Response duration, time to progression and survival were measured from the date of initiation of therapy. All patients were considered evaluable for toxicity and response. The minimum number of patients accrued in the study was that proposed by Grant et al (1992) . Twenty patients were enrolled for the first stage. If none of the original 20 patients responded, the drug was inactive and the study terminated. If four responses were observed in the first group of patients the study was to be terminated. If one to three responses were observed, an additional 15 patients were to be enrolled in the second phase. This design permits the exclusion of a response rate greater than 10.9% at the 90% confidence level if no responses were observed in the first phase. With greater true response rates, the probability of declaring a drug active is 0.82 at a true response rate of 16%.
RESULTS
Between December 1994 and June 1996, 24 patients with relapsed SCLC were treated with paclitaxel. Table 1 lists patient and disease characteristics. One patient with a mixed adeno/small-cell carcinoma of the lung and one patient with a small-cell carcinoma of the oesophagus with multiple lung metastases were included in this study. Their median age was 56 years, with a range of 39-73 years; 83% were male and all but three patients were ambulatory (ECOG performance status 0-2). The median number of previous chemotherapy regimens administered was two, range 1-3. All patients had received cyclophosphamide, doxorubicin and etoposide combination chemotherapy in the induction phase, and a number of different regimens as second-line chemotherapy. For 11 of the last group of patients, second-line chemotherapy consisted of platinum-containing regimens. Eleven patients received radiotherapy, either to the primary tumour and regional lymph nodes (n = 8) or towards brain metastases (n = 3). The total number of paclitaxel cycles administered was 69, median 3. In 14 patients it was possible to escalate the second dose of paclitaxel, although dose reductions as specified by the protocol were not necessary. In one patient, a single cycle of paclitaxel had to be delayed for 7 days because of incomplete haematological recovery on day 21. All other cycles of paclitaxel were administered as scheduled.
Toxicity
Complications of treatment were reported according to WHO criteria. In case these criteria did not apply, common toxicity criteria were used. Response, time to progression and survival All available patients had at least one two-dimensional measurable lesion. Two patients experienced early death, i.e. death before the first follow-up. These patients are excluded from the survival analysis, as is the patient who experienced toxic death in his first cycle. There were no CRs; however, there were seven PRs (29%). Five patients had SD and nine had progressive disease after one (n = 4) or two (n = 5) cycles of paclitaxel. Of the 11 patients who received platinum-containing chemotherapy for second line treatment, three obtained a PR, three had SD and five progressed after paclitaxel treatment. In one patient, disease stabilization in a metastatic site (liver) was observed, whereas a partial response was observed in the primary tumour. A second patient had a response in the liver but had progressive brain metastases. In the other patients included into this study, no evidence of differential response was observed. The median (range) response duration was 108 (64-243) days for the seven patients who responded to treatment. Median (range) time to progression was 65 (33-243) days for the 17 patients who received two or more courses of paclitaxel. Twenty-one patients were considered evaluable for survival; the median survival time was 100 (range 23-262) days.
DISCUSSION
One of the key problems in the management of SCLC is to overcome the emergence of drug-resistant relapses. Few drugs or drug combinations are capable of effecting tumour regression in the setting of an early relapse, i.e. within 3 months off induction chemotherapy. Platinum-based combinations are probably most effective in this situation, but response rates and response duration of such regimens are disappointingly low (Andersen et al, 1990) . New drugs with new mechanisms of action are clearly needed for these poor prognosis patients.
Here, we report the efficacy of paclitaxel 175 mg m-2 every 3 weeks in drug-resistant SCLC. A major response rate of 29% (95% CI 12-51%) was obtained at the cost of manageable toxicity. In the face of the heavy pretreatment, the incidence of WHO grade III/IV haematological toxicity was low and mainly characterized by leucocytopenia. This is also illustrated by the fact that in 14 patients the second dose of paclitaxel could be escalated according to protocol to 200 mg m-2 and no patient required subsequent dose reduction. There were no signs of cumulative haematological toxicity, which is in accordance with published phase I and II data on single-agent paclitaxel (Rowinsky et al, 1993) . One patient, however, died in neutropenic sepsis during his third course of paclitaxel and one patient experienced neutropenic fever in his fifth course. Non-haematological toxicity consisted mainly of myalgia and peripheral neuropathy in a minority of patients. Other toxicities were uncommon.
With a response rate of 29%, paclitaxel ranks among the most active single agents in drug-resistant SCLC. There are two reports on the activity of single-agent paclitaxel in chemotherapy naive patients with SCLC. Ettinger et al (1995) (Ruckdeschel et al, 1994) and ovarian cancer (Trimble et al, 1993) . In addition, there might be activity in anthracyclin-resistant tumours, as evidenced by responses observed in this study and anthracyclin-resistant breast cancer (Abrams et al, 1993) . The biological basis for these observations might be the different mechanism of resistance for paclitaxel. The taxanes are unique among tubulin-targeted cytotoxic drugs in that they bind to polymerized tubulin only (Schiff et al, 1979) . Alterations in the p53 gene, which occurs in over 90% of SCLC (Carbone et al, 1996) , probably confers resistance to many cytotoxic agents (Lowe et al, 1994) used in the clinical management of SCLC, but do not seem to affect sensitivity for paclitaxel (Hawkins et al, 1996; Wahl et al, 1996; Safran et al, 1996) . The most specific mechanism of resistance for paclitaxel are alterations in a-and Itubulin, resulting in impaired microtubule assembly (Dumontet et al, 1996) . Paclitaxel resistance is also conferred by the MDR phenotype, at least in vitro (Dumontet et al, 1996) , but this type of drug resistance is uncommon in SCLC in vivo (Lai et al, 1989) . Atypical multidrug resistance owing to decreased or altered levels of topoisomerase II, which is probably more important for drug resistance in SCLC, does not seem to affect sensitivity for paclitaxel in vitro (Moscow et al, 1996) .
Response duration and survival observed in this study was disappointingly short, with most responding patients progressing during paclitaxel therapy. Such short-lived responses are a common feature of single-agent therapy in drug-resistant SCLC (Andersen et al, 1990) . Nevertheless, we feel that further studies of paclitaxel combinations in resistant SCLC are warranted. In addition, the data obtained in this study and preliminary reports on paclitaxel combinations in chemotherapy naive patients suffering from SCLC (Hainsworth et al, 1996 (Hainsworth et al, , 1997 Nair et al, 1997) suggest that paclitaxel should be investigated in a first-line combination for SCLC. A good candidate for such a combination is platinum because of its synergy with paclitaxel in vitro (Jekunen et al, 1994) . Such a study in a similar group of patients as described in this report is currently underway in our institutions. With the finding of a new non-crossresistant chemotherapy regimen, the still unanswered question of the value of alternating non-cross-resistant chemotherapy might be adressed in a new study.
